BELLUS Health Inc. (BLU.TO)

10.30 -0.10 (-0.96%) At close: 04:00PM EDT

BELLUS Health Inc.

275 Armand-Frappier Boulevard
Laval, QC H7V 4A7
Canada

https://www.bellushealth.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 40

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Roberto Francesco Bellini	Pres, CEO & Director	353.03k	N/A	1980
Mr. Ramzi Benamar	Chief Financial Officer	607.33k	N/A	1973
Dr. Denis Garceau	Chief Scientific Officer	431.87k	N/A	1957
Mr. Tony Matzouranis	Sr. VP of Bus. Devel.	272.89k	N/A	1973
Dr. Catherine M. Bonuccelli M.D.	Chief Medical Officer	703.77k	N/A	1958
Dr. Andreas Orfanos FFPM, M.B.B.Ch, MBA	Chief Operating Officer	N/A	N/A	1959
Mr. Daniel Matthews	Director of Investor Relations & Communications	N/A	N/A	N/A
Mr. Sebastien Roy	Corp. Sec.	N/A	N/A	1976

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.

Corporate Governance

BELLUS Health Inc.’s ISS Governance QualityScore as of February 1, 2023 is 9. The pillar scores are Audit: 3; Board: 10; Shareholder Rights: 7; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.